Skip to content
Cultural Foundation
Author:
Click Therapeutics
FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
October 5, 2026
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
April 9, 2026